Advertisement

To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis

      Highlights

      • ACC/AHA 2013 guidelines identify 4 statin benefit groups in high CV risk patients.
      • High intensity statins (ATV 40 and 80 mg and RSV 20 and 40 mg) are recommended.
      • The VOYAGER database includes 32,258 patients from 37 randomized clinical studies.
      • LSM % change and achievement of the anticipated 50% LDL-C reduction were evaluated.
      • The choice and dose of statin impact both endpoints; overall and within each group.

      Abstract

      Background

      The 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines identify four patient groups who benefit from moderate- or high-intensity statin treatment; those with: 1) atherosclerotic cardiovascular disease (ASCVD); 2) low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dl; 3) diabetes; or 4) a 10-year ASCVD risk ≥7.5%. High-intensity statins, anticipated to reduce LDL-C by ≥50%, were identified as rosuvastatin 20–40 mg and atorvastatin 40–80 mg.

      Methods and Results

      Individual patient data (32,258) from the VOYAGER database of 37 studies were used to calculate least-squares mean (LSM) percentage change in LDL-C during 8496 patient exposures to rosuvastatin 20–40 mg, and atorvastatin 40–80 mg in the four patient benefit groups. LSM percentage reductions in LDL-C with rosuvastatin 20 and 40 mg were greater than with atorvastatin 40 mg, overall and in each statin benefit group, and with rosuvastatin 40 mg were greater than with atorvastatin 80 mg overall and in three of the four benefit groups (all p < 0.05). For example, in the ASCVD group, 40%, 59%, 57% and 71% of patients treated with atorvastatin 40 mg, atorvastatin 80 mg, rosuvastatin 20 mg and rosuvastatin 40 mg, respectively, had a ≥50% reduction in LDL-C.

      Conclusions

      The choice and dose of statin have an impact both on the percentage LDL-C reduction and achievement of ≥50% reduction in LDL-C, overall and within each of the four statin benefit groups outlined by the 2013 ACC/AHA guidelines. This may be of importance for clinicians in their choice of treatment for individual patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Catapano A.L.
        • Reiner Z.
        • De Backer G.
        • Graham I.
        • Taskinen M.R.
        • Wiklund O.
        • Agewall S.
        • Alegria E.
        • Chapman M.
        • Durrington P.
        • Erdine S.
        • Halcox J.
        • Hobbs R.
        • Kjekshus J.
        • Filardi P.P.
        • Riccardi G.
        • Storey R.F.
        • Wood D.
        European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Atherosclerosis. 2011; 217: 3-46
        • Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members
        An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia.
        J. Clin. Lipidol. 2014; 8: 29-60
        • Stone N.J.
        • Robinson J.
        • Lichtenstein A.H.
        • Bairey Merz C.N.
        • Lloyd-Jones D.M.
        • Blum C.B.
        • McBride P.
        • Eckel R.H.
        • Schwartz J.S.
        • Goldberg A.C.
        • Shero S.T.
        • Gordon D.
        • Smith Jr., S.C.
        • Levy D.
        • Watson K.
        • Wilson P.W.
        Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline.
        J. Am. Coll. Cardiol. 2014; 63: 2889-2934
        • Jackevicius C.A.
        How do the 2013 cholesterol guidelines compare with previous cholesterol guideline reports?.
        Circ. Cardiovasc Qual. Outcomes. 2014; 7: 306-310
        • Nicholls S.J.
        • Brandrup-Wognsen G.
        • Palmer M.
        • Barter P.J.
        Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
        Am. J. Cardiol. 2010; 105: 69-76
        • Karlson B.W.
        • Nicholls S.J.
        • Lundman P.
        • Palmer M.K.
        • Barter P.J.
        Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: results from VOYAGER.
        Atherosclerosis. 2013; 228: 265-269
        • Palmer M.K.
        • Nicholls S.J.
        • Lundman P.
        • Barter P.J.
        • Karlson B.W.
        Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
        Eur. J. Prev. Cardiol. 2013; 20: 1080-1087
        • Karlson B.W.
        • Barter P.J.
        • Palmer M.K.
        • Lundman P.
        • Nicholls S.J.
        Comparison of effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
        Nutr. Metab. Cardiovasc. Dis. 2012; 22: 697-703
        • Roberts W.C.
        Two more drugs for dyslipidemia.
        Am. J. Cardiol. 2004; 93: 809-811
        • Roberts W.C.
        The rule of 5 and the rule of 7 in lipid-lowering by stain drugs.
        Am. J. Cardiol. 1997; 80: 106-107
        • Boekholdt S.M.
        • Hovingh G.K.
        • Mora S.
        • Arsenault B.J.
        • Amarenco P.
        • Pedersen T.R.
        • LaRosa J.C.
        • Waters D.D.
        • DeMicco D.A.
        • Simes R.J.
        • Keech A.C.
        • Colquhoun D.
        • Hitman G.A.
        • Betteridge D.J.
        • Clearfield M.B.
        • Downs J.R.
        • Colhoun H.M.
        • Gotto Jr., A.M.
        • Ridker P.M.
        • Grundy S.M.
        • Kastelein J.J.
        Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
        J. Am. Coll. Cardiol. 2014; 64: 485-494
      1. Cholesterol treatment trialists' collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681